open access

Vol 18, No 5 (2013)
Published online: 2013-09-01
Submitted: 2012-05-14
Get Citation

Prostate embryonal rhabdomyosarcoma in adults: Case report and review of literature

Patrizia Ciammella, Maria Galeandro, Nunziata D’Abbiero, Tamara Palmieri, Elisa Donini, Cinzia Iotti
DOI: 10.1016/j.rpor.2013.03.007
·
Rep Pract Oncol Radiother 2013;18(5):310-315.

open access

Vol 18, No 5 (2013)
Published online: 2013-09-01
Submitted: 2012-05-14

Abstract

Introduction

Prostate embryonal rhabdomyosarcoma (ERMS) is a common tumour in infants and children, with a median occurrence age of 5 years, but it is rare in adults. It is characterized by a high degree of malignancy, both local rapid growth with formation of large pelvic masses, often leading to renal failure due to urethral obstruction, and systemic spread, commonly to the lungs, liver and bone. Several therapeutic approaches have been employed in the effort to treat prostate ERMS, but all of them have failed to gain a significant survival benefit in adult patients.

Case report

We report on a case of a stage IV prostate ERMS, approached with combined-modality treatment, with the administration of 5 courses of doxorubicin, ifosfamide and 2-mercaptoethane sulfonate sodium (mesna), and, subsequent radiotherapy to the prostatic bed (60[[ce:hsp sp="0.25"/]]Gy/30[[ce:hsp sp="0.25"/]]fxs). The patient remained free of progression of disease for about 1 year to finally experience a systemic relapse with multiple lung metastases and pleural effusion. The patient died for metastatic disease 27 months following the initial diagnosis.

Conclusion

While it remains questionable which therapeutic approach for prostate ERMS in adults is the most appropriate, our report demonstrates that a chemo-radiation combined treatment can control the prostate disease, reducing the symptoms and improving the quality of life of these patients, for the most part destined to die for systemic progression of disease.

Abstract

Introduction

Prostate embryonal rhabdomyosarcoma (ERMS) is a common tumour in infants and children, with a median occurrence age of 5 years, but it is rare in adults. It is characterized by a high degree of malignancy, both local rapid growth with formation of large pelvic masses, often leading to renal failure due to urethral obstruction, and systemic spread, commonly to the lungs, liver and bone. Several therapeutic approaches have been employed in the effort to treat prostate ERMS, but all of them have failed to gain a significant survival benefit in adult patients.

Case report

We report on a case of a stage IV prostate ERMS, approached with combined-modality treatment, with the administration of 5 courses of doxorubicin, ifosfamide and 2-mercaptoethane sulfonate sodium (mesna), and, subsequent radiotherapy to the prostatic bed (60[[ce:hsp sp="0.25"/]]Gy/30[[ce:hsp sp="0.25"/]]fxs). The patient remained free of progression of disease for about 1 year to finally experience a systemic relapse with multiple lung metastases and pleural effusion. The patient died for metastatic disease 27 months following the initial diagnosis.

Conclusion

While it remains questionable which therapeutic approach for prostate ERMS in adults is the most appropriate, our report demonstrates that a chemo-radiation combined treatment can control the prostate disease, reducing the symptoms and improving the quality of life of these patients, for the most part destined to die for systemic progression of disease.

Get Citation

Keywords

Prostate cancer; Embrional; Rhabdomyosarcoma; Adults; Radiation therapy

About this article
Title

Prostate embryonal rhabdomyosarcoma in adults: Case report and review of literature

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 18, No 5 (2013)

Pages

310-315

Published online

2013-09-01

DOI

10.1016/j.rpor.2013.03.007

Bibliographic record

Rep Pract Oncol Radiother 2013;18(5):310-315.

Keywords

Prostate cancer
Embrional
Rhabdomyosarcoma
Adults
Radiation therapy

Authors

Patrizia Ciammella
Maria Galeandro
Nunziata D’Abbiero
Tamara Palmieri
Elisa Donini
Cinzia Iotti

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl